

No drugs are currently approved for Coronavirus Disease-2019 ([COVID-19](#)), although some have been tried. In view of recent studies and [discussion](#) on [chloroquine](#) and [hydroxychloroquine](#) (HCQ), Singh et al. aimed to review existing literature and relevant websites regarding these drugs and COVID-19, [adverse](#) effects related to [drugs](#), and related [guidelines](#).

They systematically searched the PubMed database up till March 21, 2020, and retrieved all the articles published on chloroquine and HCQ and COVID-19.

Two small human studies have been conducted with both these drugs in COVID-19, and have shown significant improvement in some parameters in patients with COVID-19.

Considering minimal risk upon use, a long experience of use in other diseases, cost-effectiveness and easy availability across [India](#), they proposed that both these drugs are worthy of fast track [clinical trial](#) for treatment, and maybe carefully considered for clinical use as experimental drugs. Since HCQ has been approved for the treatment of [diabetes](#) in [India](#), it should be further researched in [diabetes](#) and COVID-19, a subgroup where significant [mortality](#) has been shown ¹⁾.

¹⁾

Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020 Mar 26;14(3):241-246. doi: 10.1016/j.dsx.2020.03.011. [Epub ahead of print] PubMed PMID: 32247211.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=chloroquine_for_covid-19_treatment

Last update: **2024/06/07 02:48**

